Regeneron Pharmaceuticals, Inc. (REGN) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-04

Business type: Franchise

How it makes money

Insurance companies and government programs pay for medicines through coverage and reimbursement.

Payors like governments and insurance companies pay for medicines because patients require them. The net profit is driven by the amount of rebates and discounts Regeneron must provide to these payors.

Rebates are essentially discounts given back to insurers to ensure the drug is covered on their preferred lists.

What protects it: the moat

Management claims that patents and intellectual property protect its medicines from competition.

Regeneron relies on legal protections to prevent other companies from making similar drugs.

However, the company faces risks from biosimilars, which are lower-cost versions of original biologic drugs.

What growth costs

Regeneron must invest heavily in research and the commercialization of its products.

To grow, the company invests in research and development for its approximately 45 product candidates.

It also incurs costs to market and sell its existing medicines to patients.

What could damage it

Failure of key business partners to commercialize products could impair Regeneron's earnings.

If key partners fail to help sell medicines, Regeneron may lose significant revenue.

This would directly undermine the company's ability to sell its products in major markets.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.

More on REGN

Other companies in Biotechnology